Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ETX2514 and Sulbactam in Healthy Adults
NCT03303924Phase 1Completed
- Sponsor
- Entasis Therapeutics
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durlobactam in Acinetobacter baumannii infection, sponsored by Entasis Therapeutics. Primary endpoints: Mean maximum observed drug concentration in blood at 6 hours, Mean Cmax in epithelial lining fluid at 6 hours and 5 more. Started Aug 2017; status: completed.
02
Drugs
durlobactam
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT03303924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303924.